Βοσνία - Ερζεγοβίνη - Κροατικά - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

pfizer bh d.o.o. - vorikonazol - prašak za otopinu za infuziju - 200 mg/1 viala - 1 bočica sa praškom za otopinu za infuziju sadrži: 200 mg vorikonazol (10 mg/ml)

Βοσνία - Ερζεγοβίνη - Κροατικά - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

alvogen pharma d.o.o. - vorikonazol - prašak za rastvor za infuziju - 200 mg/1 bočica - jedna bočica sa praškom za rastvor za infuziju sadrži: 200 mg vorikonazola

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - cjepiva - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama.

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - inzulin glulizin - Šećerna bolest - lijekovi koji se koriste u dijabetesu - liječenje odraslih, adolescenata i djece, šest godina ili starije od dijabetes melitusa, gdje je potrebno liječenje inzulinom.

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

merck sharp & dohme b.v. - sugammadex - neuromuskularna blokada - svi ostali terapeutski proizvodi - uklanjanje neuromuskularne blokade izazvane rokoronom ili vekuronomom. za stanovništvo dječjem: сугаммадекс preporučuje se samo za obične preokret рокурония-induced blokade kod djece i adolescenata.

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

viatris healthcare limited - fenofibrate, simvastatin - dislipidemije - sredstva za modifikaciju lipida - cholib je indiciran kao dodatna terapija dijeti i tjelovježbi u odraslih bolesnika visokim s mješovitim dislipidemijom za smanjenje triglicerida i povećanje razine hdl c kad ldl c razinama adekvatno upravlja pomoću odgovarajuće doze monoterapije simvastatinom.

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

novartis europharm limited - rivastigmin - dementia; alzheimer disease; parkinson disease - psychoanaleptics, - simptomatsko liječenje blage do umjereno teške alzheimerove demencije. simptomatsko liječenje blage do umjereno teške demencije kod pacijenata sa idiopatskom parkinsonovom bolešću.

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

roche registration gmbh - Обинутузумаб - leukemija, limfocitna, kronična, b-stanica - antineoplastična sredstva - kronične limfocitne leukemije (ХЛЛ)gazyvaro u kombinaciji s хлорамбуцилом indiciran za liječenje odraslih bolesnika s ranije леченным kroničnim лимфолейкозом (ХЛЛ) i s popratnim bolestima, što ih čini neprikladnim za pune doze флударабина terapije (vidi odjeljak 5. Фолликулярная limfom (fl)gazyvaro u kombinaciji s kemoterapijom, a zatim gazyvaro podržava terapije kod pacijenata postigao odgovor, indiciran za liječenje bolesnika prethodno liječenih liječenje napredne фолликулярная limfom. gazyvaro u kombinaciji s Бендамустин slijedi popravak gazyvaro indiciran za liječenje bolesnika s folikularni limfoma (fl), koji ne reagiraju, ili kod kojih se razvio tijekom ili do 6 mjeseci nakon tretmana ритуксимабом ili rituksimab-sadrže načina.

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

pierre fabre medicament - propranolol hidroklorid - hemangiom - beta blokirajuća sredstva - hemangiol is indicated in the treatment of proliferating infantile haemangioma requiring systemic therapy: , life- or function-threatening haemangioma,, ulcerated haemangioma with pain and/or lack of response to simple wound care measures,, haemangioma with a risk of permanent scars or disfigurement. , it is to be initiated in infants aged 5 weeks to 5 months.

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

vétoquinol sa - cimikoksib - mišićno-koštani sustav - psi - reljef boli i upale povezane s osteoartritisom. upravljanje perioperativnim bolovima zbog ortopedskih ili mekih tkiva.